Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients

Table 2

Factors influencing IBD-Disability Index.

		Univariate analysis	Multivariate model: backward elimination
Variables		Unadjusted OR; Risk of having pathological IBD-DI (≤3.5)	Adjusted OR; Risk of having pathological IBD-DI (≤3.5)	Adjusted OR; Risk of having pathological IBD-DI (≤3.5)
Disease
CD	203	1	1	1
UC	232	0.66 (0.45-0.97)	0.52 (0.34-0.80)	0.52 (0.34-0.80)
Age group
<45	189	1
≥45	246	1.25 (0.85-1.83)
Sex
Men	231	1
Women	204	1.26 (0.86-1.84)
Disease latency
≤1 year	335	1
>1 year	100	1.03 (0.95-1.11)
Disease duration
≤5 years	80	1
>5 years	355	1.00 (0.98-1.02)
Current smoking status
Nonsmoker	371	1
Smoker	64	0.89 (0.52-1.52)
Current alcohol intake
No	189	1	1
Yes	246	0.63 (0.43-0.93)	0.67 (0.44-1.02)
Disease activity; (pMayo or HBI)
Inactive	332	1	1	1
Active	103	5.83 (3.41-9.95)	5.61 (3.10-10.17)	5.62 (3.16-9.98)
High faecal calprotectin (>250)
No	248	1	1
Yes	187	1.69 (1.15-2.48)	1.07 (0.69-1.67)
Anaemia (, <13 males)
No	373	1	1	1
Yes	62	2.70 (1.50-4.85)	1.88 (0.98-3.62)	1.96 (1.02-3.73)
UC localization
E1/E2	123	1
E3	109	1.29 (0.77-2.17)
CD behavior
Nonstricturing, nonpenetrating	104	1
Stricturing	65	1.20 (0.64-2.25)
Penetrating	34	1.22 (0.55-2.68)
Localization
L1 terminal ileum	48	1
L2 colon or L3 ileocolon	148	1.42 (0.74-2.74)
L4 upper or upper+other	7	0.74 (0.15-3.71)
Extraintestinal manifestations
No	326	1	1	1
Yes	109	3.41 (2.12-5.48)	2.66 (1.59-4.43)	2.73 (1.65-4.53)
Immunosuppressant
No	381	1
Yes	54	1.35 (0.76-2.40)
Biologics
No	262	1
Yes	173	1.31 (0.89-1.93)
Surgery
No	320	1
Yes	115	1.50 (0.97-2.31)